ArticleScientific reports2026
The changed endemic pattern of human adenovirus from species C to B among children in 2022-2024 in Shenzhen, China.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Genomic characterization and evolutionary dynamics of human adenovirus C (HAdV-C) in Beijing (2023-2024): insights into multiple recombination and adaptive evolution.Virus evolution · 2026Article
- Risk factors for hospitalization in pediatric patients with human adenovirus infection and changes in epidemiological and clinical characteristics before and after the COVID-19 pandemic in China: a multicenter retrospective study.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
Respiratory human adenovirus (HAdV) infections pose a significant threat to children's health. This study investigated the prevalence and molecular epidemiology of respiratory HAdV in children from both hospital and community settings in Shenzhen between 2022 and 2024. Children under 14 years of age with suspected acute respiratory infections were enrolled from eight hospitals between November 2022 and June 2024, as well as from communities between October 2023 and April 2024 in Shenzhen. Respiratory specimens were collected and tested for HAdV. The positive rates of HAdV across different groups were compared using Pearson's chi-square test with the Bonferroni correction, and phylogenetic analysis was performed on the detected HAdV strains. The positivity proportion of HAdV among children in hospital was 16.7% (83/498) between September 2023 and June 2024, predominantly involving HAdV-B3 (95.2%, 20/21). This rate was significantly higher than that observed from October 2022 to June 2023 (3.4%, 11/321) (χ² = 33.676, P < 0.001), during which HAdV-C1 was the predominant subtype (77.8%, 7/9). The positive proportion of HAdV in hospitalized children was higher than that in outpatient children (χ2 = 0.275, P < 0.001), and the positive proportion of HAdV in boys was lower than that in girls in community (χ2 = 4.843, P = 0.028). No significant difference in the mean age was observed between children infected with HAdV-B and those with HAdV-C (t = 0.670, P = 0.509). The Shenzhen-2023-2-ILI-P600 strain exhibited a deletion in the 362-365 aa region of its Penton base gene. Analysis of global HAdV-C1 strains revealed that aa differences at positions 339 and 472 of the Fiber gene were closely linked to specific evolutionary branches. Global HAdV-B3 strains, while highly conserved, showed branch-associated aa differences at positions 168, 403, and 541 of the Hexon gene. The rise in HAdV positivity among pediatric patients in Shenzhen hospitals from late 2022 to late 2023 coincided with a shift in the dominant type from HAdV-C1 to HAdV-B3. Branch-specific aa differences were identified in the Fiber gene of HAdV-C1 and the Hexon gene of HAdV-B3.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.